Consequently, fimasartan ameliorates nonalcoholic fatty liver disease mainly through the activation of oxidative metabolism represented by PPARδ-AMPK-PGC-1α pathway. The gene discussed is PPARGC1A; the disease is metabolic dysfunction-associated steatotic liver disease.